Tim Boreham revisits Imagion Biosystems’ potential in this 5-1/2 page article profiling the company and discussing its recent milestones.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal